Sartorius Stedim BioOutsource Appoints Technical Sales Specialist in India

To help Indian researchers access a portfolio of excellent services from BioOutsource and Cellca

Glasgow, UK – June 29, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, is pleased to announce that its subsidiary BioOutsource has appointed Ravin Mehta as Technical Sales Specialist to enable customers to have access to Cellca and BioOutsource’s early stage development services for biosimilar drug candidates.

Prior to joining BioOutsource, Ravin spent over 10 years in biosimilar product development, where he gained experience in cGMP manufacturing as an upstream bioprocess scientist with two of India’s major biopharmaceutical companies. He also attained skills in management by supporting biologics development services for WuXi AppTec, one of Asia’s largest biopharma firms. His technical expertise is underpinned by a degree in biotechnology from Saurashtra University and an MBA in marketing from The Maharaja Sayajirao University of Baroda.

Ravin Mehta, Technical Sales Specialist at BioOutsource commented: “I am excited to be utilising my knowledge and experience of the Indian biosimilar industry to bring Cellca and BioOutsource’s leading portfolio to biopharma firms here.”

Mitch Scanlan, Director of Sales and Marketing at BioOutsource concluded: “India is a growing market for vaccine and biosimilar production and we are expanding our technical team to meet the need for accessing our unique services here. We’re delighted to have recruited a biosimilar expert like Ravin because he can explain how our analytical expertise can help scientists enter clinical programmes more rapidly and provide a competitive edge with their biologics’ development.”

For information about BioOutsource and Cellca in India, scientists should click these links:

www.biooutsource.com/biosimilars/

www.biooutsource.com/cell-line-and-upstream-process-development/

 

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.